logo

Cardiff Oncology, Inc. (CRDF)



Trade CRDF now with
  Date
  Headline
4/12/2021 6:09:28 AM Cardiff Oncology: Onvansertib Phase 1b/2 Data Continues To Demonstrate Robust Response In KRAS-Mutated MCRC
2/11/2021 8:21:27 AM Cardiff : Phase 2 MCRPC Trial Data Shows Two-Fold Increase In Efficacy With Optimized Onvansertib Dosing Schedule
1/26/2021 8:27:44 AM Cardiff Oncology Gets "Study May Proceed" From FDA To Initiate Phase 2 Trial Of Onvansertib In Metastatic PDAC
1/15/2021 8:19:57 AM Cardiff Oncology Presents Data From Phase 1b/2 Study In KRAS-mutated Metastatic Colorectal Cancer
12/21/2020 4:18:49 PM Cardiff Oncology Appoints Rodney Markin As Chairman Of Board
9/30/2020 12:31:00 AM Cardiff Oncology Reports Pricing Of Public Offering Of 6.5 Mln Shares At $13.50/Shr
9/29/2020 4:03:12 PM Cardiff Oncology Announces Proposed Public Offering
6/15/2020 8:45:22 AM Cardiff Data Shows Efficacy, Safety Of Onvansertib In Patients With Difficult-to-Treat Relapsed/Refractory AML
5/29/2020 8:36:27 AM Cardiff Oncology Announces Addnl Positive Efficacy Data Of Onvansertib At ASCO
5/28/2020 8:18:17 AM Cardiff Oncology Announces Fast Track Designation Granted By The FDA To Onvansertib